A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

MLA

Mirjam Kuipers, et al. “A First-in-Man Phase 1 Study of the DNA-Dependent Protein Kinase Inhibitor Peposertib (Formerly M3814) in Patients with Advanced Solid Tumours.” British Journal of Cancer, vol. 124, Jan. 2021, pp. 728–35. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8a65e8cb8640861d31d96ecf577c12d9&authtype=sso&custid=ns315887.

APA

Mirjam Kuipers, Ivan Diaz-Padilla, Morten Mau-Sørensen, Barbara Sarholz, Maja J.A. de Jonge, Dorte Nielsen, Ahmad Awada, Henk M.W. Verheul, Karin Berghoff, Jan H.M. Schellens, Lars Damstrup, Samer El Bawab, Patrick Schöffski, & Mark T. J. van Bussel. (2021). A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. British Journal of Cancer, 124, 728–735.

Chicago

Mirjam Kuipers, Ivan Diaz-Padilla, Morten Mau-Sørensen, Barbara Sarholz, Maja J.A. de Jonge, Dorte Nielsen, Ahmad Awada, et al. 2021. “A First-in-Man Phase 1 Study of the DNA-Dependent Protein Kinase Inhibitor Peposertib (Formerly M3814) in Patients with Advanced Solid Tumours.” British Journal of Cancer 124 (January): 728–35. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8a65e8cb8640861d31d96ecf577c12d9&authtype=sso&custid=ns315887.